Sichuan Baili (Biokin, SystImmune)
China
FollowEvery new trial, moved date and filing, and a Monday email
Furthest along
5 in Phase 3
6 in Phase 2
Drugs
19
in active trials · 22 in all
Trials
138 active
143 since 2021
Drugs19
| Drug | How it works | Partner | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
EGFR/HER3 bispecific antibody-drug conjugate |
Bristol Myers Squibb |
Phase 3 | Nov 2026soonPhase 3 trial completes | ||
| Next date | Nov 2026 · Phase 3 trial completes | ||||
| Also tested for | Non-small Cell Lung Cancer, Solid Tumor and 44 more | ||||
| Open drug page | |||||
— |
Phase 3 | Nov 2026soonPhase 2 trial completes | |||
| Next date | Nov 2026 · Phase 2 trial completes | ||||
| Also tested for | Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer and 6 more | ||||
| Open drug page | |||||
HER2-targeted antibody-drug conjugate |
Phase 3 | Dec 2026Phase 1/2 trial completes | |||
| Next date | Dec 2026 · Phase 1/2 trial completes | ||||
| Also tested for | HER2-positive Breast Cancer, Breast Cancer and 36 more | ||||
| Open drug page | |||||
— |
Phase 2/3 | Dec 2027Phase 2/3 trial completes | |||
| Next date | Dec 2027 · Phase 2/3 trial completes | ||||
| Also tested for | Relapsed/Refractory Acute Myeloid Leukemia (R/R AML), Acute Myeloid Leukemia and 1 more | ||||
| Open drug page | |||||
BL-M14D1not checked |
— |
Phase 3 | Dec 2027Phase 2 trial completes | ||
| Next date | Dec 2027 · Phase 2 trial completes | ||||
| Also tested for | Small Cell Lung Cancer, Neuroendocrine Tumors and 20 more | ||||
| Open drug page | |||||
— |
Phase 2 | Nov 2026soonPhase 2 trial completes | |||
| Next date | Nov 2026 · Phase 2 trial completes | ||||
| Also tested for | Solid Tumor, Non-small Cell Lung Cancer and 10 more | ||||
| Open drug page | |||||
— |
Phase 1/2 | Dec 2026Phase 1/2 trial completes | |||
| Next date | Dec 2026 · Phase 1/2 trial completes | ||||
| Also tested for | Hematologic Malignancies, Breast Cancer and 2 more | ||||
| Open drug page | |||||
— |
Phase 1/2 | Dec 2026Phase 1/2 trial completes | |||
| Next date | Dec 2026 · Phase 1/2 trial completes | ||||
| Also tested for | Non Hodgkin Lymphoma, Acute Lymphoblastic Leukemia and 9 more | ||||
| Open drug page | |||||
— |
Phase 2 | Dec 2028Phase 1/2 trial completes | |||
| Next date | Dec 2028 · Phase 1/2 trial completes | ||||
| Also tested for | Solid Tumors, Solid Tumor and 7 more | ||||
| Open drug page | |||||
— |
Phase 2 | Dec 2028Phase 2 trial completes | |||
| Next date | Dec 2028 · Phase 2 trial completes | ||||
| Also tested for | Solid Tumor, Solid Tumors and 4 more | ||||
| Open drug page | |||||
— |
Phase 1/2 | — | |||
| Also tested for | Breast Cancer, Locally Advanced or Metastatic Digestive Tract Tumors and 2 more | ||||
| Open drug page | |||||
— |
Phase 1 | Dec 2026Phase 1 trial completes | |||
| Next date | Dec 2026 · Phase 1 trial completes | ||||
| Also tested for | Recurrent Glioma, Solid Tumor | ||||
| Open drug page | |||||
— |
Phase 1 | Jun 2027Phase 1 trial completes | |||
| Next date | Jun 2027 · Phase 1 trial completes | ||||
| Also tested for | Solid Tumor, Breast Cancer and 2 more | ||||
| Open drug page | |||||
— |
Phase 1 | Nov 2027Phase 1 trial completes | |||
| Next date | Nov 2027 · Phase 1 trial completes | ||||
| Also tested for | Solid Tumor, Non Small Cell Lung Cancer and 5 more | ||||
| Open drug page | |||||
— |
Phase 1 | Dec 2027Phase 1 trial completes | |||
| Next date | Dec 2027 · Phase 1 trial completes | ||||
| Also tested for | Solid Tumors, Gastrointestinal Tumors and 3 more | ||||
| Open drug page | |||||
— |
Phase 1 | Dec 2027Phase 1 trial completes | |||
| Next date | Dec 2027 · Phase 1 trial completes | ||||
| Also tested for | Solid Tumors, Gastrointestinal Tumors | ||||
| Open drug page | |||||
— |
Phase 1 | Oct 2028Phase 1 trial completes | |||
| Next date | Oct 2028 · Phase 1 trial completes | ||||
| Also tested for | Solid Tumor, Solid Tumors and 14 more | ||||
| Open drug page | |||||
— |
Phase 1 | — | |||
| Also tested for | Solid Tumor, Head and Neck Squamous Cell Carcinomas and 1 more | ||||
| Open drug page | |||||
— |
Phase 1 | — | |||
| Also tested for | Solid Tumor, Esophageal Cancer and 4 more | ||||
| Open drug page | |||||
No drugs match “”.
About
- No active trial
- FOLFIRI Protocol, FOLFOX Protocol, SI-F019
- SEC filings
- None: it does not file with the US SEC
- Registry names
- 2 names in ClinicalTrials.gov Sichuan Baili Pharmaceutical Co., Ltd.
SystImmune Inc. - Sources
- ClinicalTrials.gov updated 16 Nov 2026 Industry-sponsored drug trials since 2021 · Logos provided by Logo.dev